PT-141
FDA ApprovedLast reviewed
Also known as: Bremelanotide, Vyleesi
PT-141 (Bremelanotide) is an FDA-approved melanocortin agonist prescribed as Vyleesi for hypoactive sexual desire disorder in premenopausal women, also studied for male erectile dysfunction.
Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
§ AI Reference Summary
PT-141 (also known as Bremelanotide, Vyleesi) is a prominently researched experimental compound classified strictly within the Melanocortin Agonist framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects. with a documented biological half-life of roughly 2.7 hours, In preclinical investigative trials and independent academic studies, researchers utilizing PT-141 have documented significant, quantifiable biological outcomes, primarily focusing on sexual arousal, libido. Typical research protocols investigate administering 1500 to 1500mcg via subq pathways 2x/wk. However, it is critically important to understand that while PT-141 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
§ Mechanism of Action
Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
§ Primary Benefits
- 1Sexual arousal
- 2libido
§ Clinical Evidence
PT-141 (Bremelanotide) for hypoactive sexual desire Phase 3
Kingsberg et al. (Obstet. & Gynecol.): Two identical Phase 3 RECONNECT trials showing bremelanotide significantly improves sexual desire and reduces distress in premenopausal women with HSDD.
Very StrongBremelanotide Phase 3 efficacy and safety in HSDD
Clayton et al.: Phase 3 data confirming statistically significant improvements in desire metrics with favorable safety profile (nausea, flushing, headache). Led to FDA approval.
Very StrongPT-141 induces erection in men with erectile dysfunction
Diamond et al.: Double-blind, placebo-controlled study showing PT-141 induces significant erectile response at >7mg doses, effective even in PDE5 inhibitor non-responders.
StrongBremelanotide mechanism of action and pharmacology review
Comprehensive review of bremelanotide's MC4R mechanism, pharmacokinetics, clinical trial efficacy, and safety data across male and female sexual dysfunction studies.
StrongStrategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
A 2025 review found that pharmacological agents like bremelanotide demonstrated efficacy for managing low sexual desire in breast and gynecologic cancer survivors. The analysis investigated multimodal treatment strategies, emphasizing the need for individualized care to address treatment-related sexual dysfunction.
ModerateGateways to clinical trials.
A study published in Methods and findings in experimental and clinical pharmacology investigating the effects and mechanisms.
ModerateGateways to clinical trials.
A study published in Methods and findings in experimental and clinical pharmacology investigating the effects and mechanisms.
ModerateGateways to clinical trials.
A study published in Methods and findings in experimental and clinical pharmacology investigating the effects and mechanisms.
ModerateGateways to clinical trials.
A study published in Methods and findings in experimental and clinical pharmacology investigating the effects and mechanisms.
ModerateGateways to clinical trials.
A study published in Methods and findings in experimental and clinical pharmacology investigating the effects and mechanisms.
Moderate§ Safety Profile
Nausea/hypertension possible. FDA-approved (Vyleesi) for HSDD in premenopausal women. Limited to 8 doses/month.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
RouteSubQ
Dose Range1500–1500 mcg
Frequency2x/wk
Timing45 min before activity
BAC Water2.5 ml / 10mg vial
FDA-approved dose: 1.75mg SubQ as needed. Max 1 dose per 24h, 8 doses/month.
§ Pharmacokinetics
⏱️ Half-Life: 2.7h
Plasma concentration over time§ Regulatory
🇺🇸USA
FDA/TGA Approved🇨🇦Canada
Research Only🇬🇧UK
Unregulated🇪🇺EU
Unregulated🇦🇺Australia
Research OnlyLast updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
§ Expected Outcomes
Week 1
Libido enhancement typically onset within 45 minutes of dosing
Weeks 2–4
Consistent improvement in sexual response and desire
Month 2–3
Psychological effects may plateau; effectiveness maintained with intermittent use
Long-term
FDA-approved for long-term use; limit to 8 doses/month
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From Phase 3 RECONNECT trial data | ~40% of users | moderate |
Flushing | ~20% of users | mild |
Headache | ~10% of users | mild |
Transient blood pressure increase Avoid if uncontrolled hypertension | ~8% of users | moderate |
Where to Source PT-141 for Research
Finding verified, high-purity PT-141 requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified PT-141✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Reconstitution CalculatorCalculate reconstitution for PT-141 →
Compare ToolCompare PT-141 to similar peptides →
Frequently Asked Questions
§ Comparisons
Cite This Page
Free Download
2026 Peptide Stack Cheat Sheet
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author
Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...
View Full ProfileLast fact-checked: · PeptiDex Editorial Team
⚠ Educational only · Not medical advice · Most peptides are research-only / not FDA-approved